Skip to Main Content

Sigmapharm Laboratories Wins Claim Construction

November 01, 2018

Related Industry:

Life Sciences
Client Success

Husch Blackwell client Sigmapharm Laboratories, LLC scored a victory in bringing to market a therapeutic equivalent of Eliquis. Sigmapharm argued for a claim construction of “pharmaceutically acceptable salt,” and the Court adopted Sigmapharm’s proposed construction verbatim.

This result is one of the first major steps in obtaining a favorable outcome for our client and potentially saving billions of dollars for payors. Among 25 original defendants—9 of which remain in the litigation—Husch attorneys took the lead in briefing the position, and Phil Segrest handled the oral argument.


Marc R. Wezowski

Of Counsel

Don J. Mizerk


Dustin L. Taylor

Senior Associate

Syed Rizvi, Ph.D.

Senior Scientific Advisor

Stay updated.

Subscribe to receive Husch Blackwell’s news and insights.

Select your preferences